Commentary|Articles|November 19, 2026

Treatment Sequencing and Toxicity Are Top Concerns in HER2-Mutant NSCLC

Fact checked by: Jonah Feldman
Listen
0:00 / 0:00

During a live event, Amy Cummings, MD, discussed a patient case of a 69-year-old man with non–small cell lung cancer and an HER2 exon 20 insertion mutation.

Zongertinib (Hernexeos) and sevabertinib (Hyrnuo) each carry FDA accelerated approval for first-line treatment of HER2-mutant non–small cell lung cancer (NSCLC), based on single-arm response data. The first randomized phase 3 trial in this setting, DESTINY-Lung04 (NCT05048797), showed longer progression-free survival (PFS) with trastuzumab deruxtecan (T-DXd; Enhertu) than with chemoimmunotherapy, but overall survival (OS) did not favor T-DXd, and interstitial lung disease (ILD) was more frequent. Because no trial has compared the options head to head, frontline selection and sequencing rest largely on toxicity and clinical judgment.

In a virtual Case-Based Roundtable event for oncologists in Arizona and Nevada, Amy Cummings, MD, a thoracic oncologist at UCLA Health in Los Angeles, California, reviewed HER2 testing and first-line data for HER2-mutant NSCLC and moderated discussion of a 69-year-old man with brain metastases, and discussed how toxicity and sequencing were likely to guide selection.

Register today to join a Case-Based Roundtable near you.

This article is part 1 of a 2-part series from a Case-Based Roundtable event.

CASE SUMMARY

  • The patient is a 69-year-old man, never smoker.
  • History of diabetes and hyperlipidemia, both well controlled
  • Dyspnea on exertion, right-sided chest discomfort, and weight loss
  • Left lower lobe mass and nodules throughout the brain
  • Biopsy: thyroid transcription factor 1 (TTF-1) positive; PD-L1 10%; HER2 exon 20 insertion mutation; no other actionable alterations

What frontline treatment would you most likely offer this patient?

Zongertinib
Platinum doublet chemotherapy + immunotherapy
Trastuzumab deruxtecan
Platinum doublet alone
Sevabertinib
Clinical trial
Other

EVENT RECAP

On HER2 testing, concurrent tissue-based and liquid-based next-generation sequencing (NGS) was the most common approach, chosen in 5 of 16 votes, and 7 of 16 votes included immunohistochemistry. Suresh Mukkamala, MD, of Tucson, Arizona, said an actionable liquid biopsy result prompts treatment, with tissue awaited only when the liquid biopsy result is negative. The reason was turnaround time: “Liquid [biopsy] takes about a week. Tissue takes about 3 weeks.”

For the case patient, 11 of 15 respondents chose zongertinib as frontline therapy, 2 chose platinum doublet chemotherapy with immunotherapy, and 2 chose T-DXd. Participants said a patient’s refusal of chemotherapy or of any intravenous therapy would favor an oral agent, and pre-existing lung disease would count against T-DXd because of the risk of ILD. Christopher Chen, MD, of The Oncology Institute of Hope and Innovation in Gilbert, Arizona, said that in a lung cancer population with frequent lung disease, pulmonary toxicities “become a lot more of a red flag than in other disease states.”

Cummings presented the findings from the pivotal trials. For zongertinib, the phase 1 Beamion LUNG-1 trial (NCT04886804) reported a confirmed objective response rate (ORR) of 76% (95% CI, 65%-84%) among 74 treatment-naive patients, with a median duration of response of 15.2 months and a median PFS of 14.4 months (95% CI, 11.1-not evaluable).1 Cohort 4 enrolled 30 patients with active brain metastases, about a third of them treatment naive, and the confirmed intracranial ORR was 47% (95% CI, 30%-64%) overall and 59% among the 17 patients with measurable intracranial disease and no prior brain radiotherapy. Intracranial disease control was 87%, but intracranial responses were shorter than systemic ones, with a median duration of 6.9 months and a median intracranial PFS of 8.2 months (95% CI, 4.1-11.3).

Grade 3 or higher treatment-related adverse events occurred in 19% of patients in the first-line cohort. Diarrhea was the most frequent event at 55%, but only 3% of patients had grade 3 diarrhea, and rash occurred in 24%. Dose reductions occurred in 16% of patients and discontinuations in 9%. Cummings described diarrhea as the toxicity to counsel on at the start and said the label advises cardiac monitoring as clinically indicated, without a set interval.

For sevabertinib, a reversible tyrosine kinase inhibitor (TKI) active against exon 20 insertions and missense mutations, the FDA approval rests on the SOHO-01 trial (NCT05099172), in which 69 treatment-naive patients had a confirmed ORR of 75% (95% CI, 64%-85%) by blinded independent central review, and 73% of responders had a response lasting at least 6 months.2 Diarrhea occurred in 88%, rising to grade 3 in 5%, with no discontinuations, and hypokalemia was seen in 20% across cohorts D, E and F.

Cummings said the agents appeared broadly comparable, with somewhat more diarrhea and rash with sevabertinib, and that no data supported switching to sevabertinib after progression on zongertinib. A time-course analysis of diarrhea was presented, tying its frequency to the recency of prior therapy exposure,4 but Jiaxin Niu, MD, of HonorHealth in Scottsdale, Arizona, said that with a cohort this small, “when you slice the pie much thinner, it’s very hard to rely on this conclusion.” Cummings said she sends patients home with a loperamide prescription to take before the first dose.

DESTINY-Lung04 randomly assigned 454 patients 1:1 to T-DXd or pembrolizumab (Keytruda) plus platinum chemotherapy and pemetrexed.5 Median PFS by blinded independent central review was 14.3 months with T-DXd vs 8.3 months with chemoimmunotherapy (HR, 0.63; 95% CI, 0.50-0.79; P < .0001), and ORR was 70% vs 44.5%. Median OS was 29.3 months vs 33.1 months (HR, 1.15; 95% CI, 0.88-1.52), a difference that was not statistically significant. Drug-related ILD occurred in 20.8% of patients receiving T-DXd vs 2.3% receiving chemoimmunotherapy, mostly grade 1 or 2, and 4 drug-related deaths occurred with T-DXd vs 1 with chemoimmunotherapy. The investigators attributed the lack of OS benefit to imbalanced subsequent therapy between the arms, and the trial was open label.

Niu said HER2-mutant disease behaves like EGFR-mutant disease in its response to immunotherapy: “I have never seen anybody who responded.” Robert Yoo, DO, of Ironwood Cancer & Research Center in Scottsdale, Arizona, pointed to immune-cold tumor biology as the reason immunotherapy performs poorly, and said the control arm’s result did not surprise him. Cummings noted that a patient randomly assigned to chemoimmunotherapy vs zongertinib did have a complete response, so a small subset may still benefit.

Surabhi Amar, MD, of Valleywise Health in Phoenix, Arizona, noted that DESTINY-Lung04 is the only phase 3 dataset, but said the risk of grade 5 toxicity and patient preference for an oral drug would still lead to starting with zongertinib. On sequencing, Yoo said that after progression on a frontline TKI, “I would not be hesitant to use [T-DXd],” because evidence for the drug in HER2-mutant disease had been weak before this trial.

Cummings expected combination strategies to be the next focus, since progression-free survival with these agents rarely approaches 2 years.

Register today to join a Case-Based Roundtable near you.

DISCLOSURES: Cummings previously reported grant support from LUNGevity and AstraZeneca; consulting fees from Oncohost and TEMPUS; and a leadership role in Los Angeles County Lung Cancer Coalition.

REFERENCES
1. Heymach JV, Ruiter G, Ahn MJ, et al. Zongertinib in Previously Treated HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2025;392(23):2321-2333. doi:10.1056/NEJMoa2503704
2. Loong HH, Le X, Prelaj A, et al. SOHO-01: Updated safety and efficacy of sevabertinib in patients with advanced HER2-mutant non-small cell lung cancer (NSCLC). J Clin Oncol. 2026;44(suppl 16):8622. doi:10.1200/JCO.2026.44.16_suppl.8622
3. Le X, Kim TM, Loong HH, et al. Sevabertinib in advanced HER2-mutant non-small-cell lung cancer. N Engl J Med. 2025;393(18):1819-1832. doi:10.1056/NEJMoa2511065
4. Girard N, Kim TM, Loong HH, et al. Characterization and management of sevabertinib-induced diarrhea in the SOHO-01 study. Presented at: European Lung Cancer Congress; March 25-28, 2026; Copenhagen, Denmark. Poster 18P.
5. Rotow J, Okamoto I, Goto K, et al. First-line trastuzumab deruxtecan (T-DXd) in metastatic HER2-mutant NSCLC: DESTINY-Lung04 primary results. J Thorac Oncol. 2026;21(10 suppl):104267. doi: 10.1016/j.jtho.2026.104267

Related to this article